IMPORTANT SAFETY INFORMATION

Text
Size
RILUTEK can give you more time. This extra time offers you and your loved ones the
chance to adjust to the news and prepare for the future. You can still plan events
and activities with those who matter most to you.
More than 1,100 people with ALS have taken part in RILUTEK medical studies. In these
medical studies, people who took RILUTEK lived an average of 2-3 months longer than
people who took a
placebo (sugar pill). However, after 18 months of treatment, there was no
difference between those who took RILUTEK and those who took a
placebo. What this means is that, in clinical trials, RILUTEK offered a
survival benefit early in ALS treatment.
And for people who took RILUTEK, compared to those who took a sugar pill, there
was a longer time between starting treatment and the need for a
tracheostomy. This surgical procedure creates an opening in a pa tient’s
windpipe to allow access to a machine to help with breathing. People with ALS usually
get this procedure as their disease progresses.
Early treatment, early benefits
It has been shown that the benefits of RILUTEK are seen early in treatment. If your
doctor starts you on treatment with RILUTEK after being diagnosed with ALS, you
will be taking an active role in coping with the disease. This may help you feel
more positive. And by not delaying treatment, you will help improve disease management.